molecules of the month


oral gamma secretase inhibitor

Ph. III for DT/AF + Ph. II for OvGCTs

opt. of diamide amino imidazole GSIs

Press release, February 27, 2023 / NEJM, March 9, 2023

Pfizer / SpringWorks Therapeutics, Inc.

nirogacestat, oral gamma secretase inhibitor, Ph. III for DT/AF + Ph. II for OvGCTs, single-digit nanomolar potency for Aβ reduction in vitro, Press release, February 27, 2023, PFIZER / SPRINGWORKS THERAPEUTICS, INC.
8 mins read

Upcycling a γ-secretase inhibitor for a potentially first- & best-in-class treatment for aggressive desmoid tumors. Nirogacestat was recently granted FDA priority review for rare, aggressive, locally invasive, soft-tissue desmoid tumors (DTs). This reversible, non-competitive gamma secretase inhibitor (GSI) draws its anticancer activity from its ability to block Notch signaling, and is the lead drug from a 2017 Pfizer spinout, SpringWorks Therapeutics. While not metastatic or life-threatening, desmoid tumors can compress vital organs, causing nerve damage, severe pain and intestinal complications, and there are no FDA-approved treatments. Therapeutic approaches for DT include robust chemotherapy, radiation and TKI treatments, but these are often poorly tolerated and inconsistently efficacious. For these reasons, nirogacestat has been granted Fast Track, Breakthrough Therapy and Orphan Drug…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: